Skip to main content
    A

    Arcutis Biotherapeutics Inc (ARQT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $27.15
    -1.11 (-3.93%)

    Market Cap: $3.57B

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Arcutis Biotherapeutics Inc (ARQT) P/E Ratio & Valuation Multiples

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Arcutis Biotherapeutics (ARQT) trades at 129.3x trailing earnings and 7.0x sales. Its P/B of 14.6x is above its 5-year median of 7.1x. Its forward P/E is 31.9x.

    Current Multiples

    Its forward P/E is below its trailing P/E, which implies earnings per share about 305.3% higher over the next year.

    MultipleValue
    P/E (trailing)129.3x
    Forward P/E31.9x
    Price to sales7.0x
    Price to book14.6x
    EV/EBITDA114.9x
    PEGN/A
    As of Nov 17, 2026

    Historical Medians

    MultipleCurrent5-year median10-year median
    P/B14.6x7.1xN/A
    Medians of month-end values through Oct 2026: 60 months (5-year).

    Valuation History

    Over the 4 of the 6 year ends shown that have a P/S, its P/S ranged from 3.6x in 2023 to 241.5x in 2022.

    Year endPriceP/SP/B
    2025$29.0410.0x20.8x
    2024$13.938.5x10.7x
    2023$3.233.6x3.4x
    2022$14.80241.5x4.3x
    2021$20.74N/A3.5x
    2020$28.13N/A4.5x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported.

    GNG Valuation

    GNG viewFairly valued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About ARQT

    What is ARQT's forward P/E ratio?

    Arcutis Biotherapeutics has a forward P/E ratio of 31.9x.

    Is ARQT stock overvalued?

    GNG's valuation label for ARQT is Fairly valued.

    What is ARQT's price to sales ratio?

    Arcutis Biotherapeutics has a price to sales ratio of 7.0x.